A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion

Abstract BACKGROUND: We sought to evaluate the systemic and ocular risk factors for severity on visual acuity and central retinal thickness in macular edema secondary to retinal vein occlusion (RVO-ME). METHODS: This retrospective study included 46 RVO-ME patients in The First Affiliated Hospital of Sun Yat-sen University from January 2015 to November 2019. Systemic examinations include blood pressure, blood glucose, blood lipids, vascular endothelial function, and carotid artery color ultrasound. Ocular examinations include the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT). The integrity of the outer retina was evaluated as well. According to the baseline BCVA and CRT levels, the patients were divided into high vision group and low vision group, high CRT group, and low CRT group. Multivariate logistic regression analyses were performed to analyze the risk factors on baseline BCVA and CRT.RESULTS: We enrolled 19 eyes of CRVO (central retinal vein occlusion) and 27 eyes of BRVO (branch retinal vein occlusion). We identified 31 (67.4%) as high CRT and 23 (50.0%) as poor VA of 46 patients on admission. There were 15 cases of BRVO in the high CRT group (48.4%) and 12 cases in the low CRT group (80.0%). The type of disease (BRVO/CRVO) was an independent factor of baseline CRT (P=0.017). Endothelial dysfunction correlates with baseline BCVA independently (P=0.038). Ellipsoidal zone (EZ) destruction was found in 19 cases (82.6%) in the low vision group and 6 cases (26.1%) in the high vision group. EZ integrity correlates with baseline BCVA independently (P=0.017). CONCLUSION: The central retinal vein occlusion (CRVO) has markedly higher CRT than branch retinal vein occlusion (BRVO). Endothelial dysfunction and disrupted ellipsoidal zone were significantly associated with poor baseline VA on admission.

Download Full-text

Dexamethasone intravitreal implant in patients with macular oedema related to branch or central retinal vein occlusion, a retrospective study

Acta Ophthalmologica ◽

10.1111/j.1755-3768.2012.s032.x ◽

2012 ◽

Vol 90 ◽

pp. 0-0

Author(s):

M BENZERROUG ◽

M SERRERO ◽

D BREMOND-GIGNAC ◽

S MILAZZO

Keyword(s):

Retrospective Study ◽

Retinal Vein Occlusion ◽

Central Retinal Vein Occlusion ◽

Macular Oedema ◽

Dexamethasone Intravitreal Implant ◽

Vein Occlusion ◽

Intravitreal Implant ◽

Central Retinal Vein

Download Full-text

Platelet Coagulant Activities and Retinal Vein Thrombosis

Thrombosis and Haemostasis ◽

10.1055/s-0038-1651475 ◽

1977 ◽

Vol 38 (02) ◽

pp. 0399-0406 ◽

Cited By ~ 10

Author(s):

Peter N. Walsh ◽

Richard E. Goldberg ◽

Richard L. Tax ◽

Larry E. Magargal

Keyword(s):

Platelet Aggregation ◽

Venous Thrombosis ◽

Retinal Vein Occlusion ◽

Serotonin Release ◽

Platelet Factor ◽

Trigger Mechanism ◽

Local Conditions ◽

Plasma Coagulation ◽

Vein Thrombosis ◽

Vein Occlusion

SummaryTo determine whether platelets play a role in the pathogenesis of retinal vein occlusion (RVO), platelets and coagulation were evaluated in 28 patients with RVO. Platelet coagulant activities concerned with the initiation and early stages of intrinsic coagulation were 2–4 fold increased in 9 patients with acute primary RVO but not in patients with acute secondary (10 patients) or chronic (9 patients) RVO. Platelet factor 3 activity, platelet aggregation, serotonin release by platelets and plasma coagulation were normal in all patients. Platelets may provide a trigger mechanism for venous thrombosis in the eye when local conditions permit.

Download Full-text

Hypercoagulability and High Lipoprotein(a) Levels in Patients with Central Retinal Vein Occlusion

Thrombosis and Haemostasis ◽

10.1055/s-0038-1648808 ◽

1994 ◽

Vol 72 (01) ◽

pp. 039-043 ◽

Cited By ~ 46

Author(s):

Francesco Bandello ◽

Silvana Vigano’ D’Angelo ◽

Mariella Parlavecchia ◽

Alessandra Tavola ◽

Patrizia Della Valle ◽

...

Keyword(s):

Retinal Vein Occlusion ◽

Central Retinal Vein Occlusion ◽

Specific Treatment ◽

Fibrin Deposition ◽

Heparin Cofactor Ii ◽

Lipoprotein A ◽

Vein Occlusion ◽

Acute Event ◽

D Dimer ◽

Central Retinal Vein

SummaryA series of coagulation parameters and lipoprotein(a) (Lp(a)) were explored in plasma from 40 patients with central retinal vein occlusion (CRVO, non-ischemic type n = 12; ischemic type n = 28) free of local and systemic predisposing factors, 1 to 12 months after the acute event. Forty age- and sex-matched patients with cataract served as controls. Prothrombin fragment 1.2 (FI.2), D-dimer, FVII:C - but not FVII: Ag - were higher and fibrinogen was lower in CRVO patients than in controls. Patients with non-ischemic CRVO had higher FI .2 and FVII:C and lower heparin cofactor II than patients with ischemic CRVO. Lp(a) levels greater than 300 mg/1 were observed in 12 patients with CRVO and in 4 controls (30% vs 10%, p <0.025). Patients with high Lp(a) - consistently associated with the S2 phenotype - had higher FVII:C, FVII:C/Ag ratio, and fibrinogen than the remaining CRVO patients. Plasma FI.2 and D-dimer correlated fairly in controls (r = 0.41) and patients with normal Lp(a) levels (r = 0.55), but they did not in the group of patients with high Lp(a) (r = 0.19), where the latter parameter was negatively related to D-dimer (r = −0.55). There was no dependence of the abnormalities observed on the time elapsed from vein occlusion. The findings of activated FVII and high FI.2, D-dimer, and Lp(a) are not uncommon in patients with CRVO. Increased thrombin formation with fibrin deposition and impaired fibrinolysis may play a role in the pathophysiology of CRVO and require specific treatment

Download Full-text